Literature DB >> 10808056

RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.

C Iarlori1, M Reale, A Lugaresi, G De Luca, L Bonanni, A Di Iorio, C Feliciani, P Conti, D Gambi.   

Abstract

RANTES (regulated upon activation, normal T-cell expressed and secreted), a CC chemokine, appears to play a role in the pathogenesis of relapsing-remitting multiple sclerosis (RR-MS), enhancing the inflammatory response within the nervous system. We have demonstrated that RANTES production is increased in RR-MS compared to controls. Interferon-beta-1b (IFN-beta-1b) treatment reduces RANTES production in sera and peripheral blood adherent mononuclear cell (PBAM) supernatants both in relapse and remission. IFN-beta-1b also reduces RANTES expression in PBAM. Our results suggest that RANTES modulation might represent one of the mechanisms of action of IFN-beta-1b in RR-MS.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10808056     DOI： 10.1016/s0165-5728(00)00261-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  8 in total

1.  Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

Authors:  Elizabeth R Comini-Frota; Antonio L Teixeira; Janaína P A Angelo; Marcus V Andrade; Doralina G Brum; Damacio R Kaimen-Maciel; Norma T Foss; Eduardo A Donadi
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

2.  Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures.

Authors:  Gilbert Besong; Giuseppe Battaglia; Mara D'Onofrio; Roberto Di Marco; Richard Teke Ngomba; Marianna Storto; Marzia Castiglione; Katia Mangano; Carla L Busceti; Ferdinando R Nicoletti; Kevin Bacon; Michael Tusche; Ornella Valenti; Peter Jeffrey Conn; Valeria Bruno; Ferdinando Nicoletti
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

Review 3.  Cytokines and myelination in the central nervous system.

Authors:  Thomas Schmitz; Li-Jin Chew
Journal:  ScientificWorldJournal       Date:  2008-11-02

Review 4.  CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis.

Authors:  Anna Pittaluga
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

5.  Palm Fruit Bioactives modulate human astrocyte activity in vitro altering the cytokine secretome reducing levels of TNFα, RANTES and IP-10.

Authors:  Robert P Weinberg; Vera V Koledova; Kirsten Schneider; T G Sambandan; Adlai Grayson; Gal Zeidman; Anastasia Artamonova; Ravigadevi Sambanthamurthi; Syed Fairus; Anthony J Sinskey; ChoKyun Rha
Journal:  Sci Rep       Date:  2018-11-06       Impact factor: 4.379

6.  Development of an Electrochemical CCL5 Chemokine Immunoplatform for Rapid Diagnosis of Multiple Sclerosis.

Authors:  Sara Guerrero; Esther Sánchez-Tirado; Lourdes Agüí; Araceli González-Cortés; Paloma Yáñez-Sedeño; José M Pingarrón
Journal:  Biosensors (Basel)       Date:  2022-08-07

7.  A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment.

Authors:  Mario Stampanoni Bassi; Fabio Buttari; Ilaria Simonelli; Luana Gilio; Roberto Furlan; Annamaria Finardi; Girolama Alessandra Marfia; Andrea Visconti; Andrea Paolillo; Marianna Storto; Stefano Gambardella; Rosangela Ferese; Marco Salvetti; Antonio Uccelli; Giuseppe Matarese; Diego Centonze; Francesca De Vito
Journal:  Genes (Basel)       Date:  2020-09-30       Impact factor: 4.096

8.  RANTES/CCL5 Signaling from Jawbone Cavitations to Epistemology of Multiple Sclerosis - Research and Case Studies.

Authors:  Johann Lechner; Volker von Baehr; Fabian Schick
Journal:  Degener Neurol Neuromuscul Dis       Date:  2021-07-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.